Gavin Oudit



Canada Research Chair in Heart Failure

Tier 2 - 2013-10-01
University of Alberta
Health

780-407-8569
gavin.oudit@ualberta.ca

Research involves


Conducting clinical trials to develop new therapies for treating different types of heart failure.

Research relevance


This research could lead to the discovery of new therapies that may prevent or treat heart failure and allow patients to live longer lives.

New Ways to Treat Heart Failure


Heart failure currently affects about 400,000 Canadians, and is on the increase. New therapies are desperately needed to treat it.

Dr. Gavin Oudit, Canada Research Chair in Heart Failure, is taking several novel approaches toward discovering drugs and treatment targets for heart-failure patients. Oudit is studying failing human hearts at multiple levels—molecular, cellular, tissue and whole organ.

Oudit’s research on calcium channel blockers, which are used to treat high blood pressure, has already shown encouraging results in early clinical trials. His research on iron-overload cardiomyopathy, a disease of the heart muscle, is also heading into a clinical trial.

In addition, Oudit’s research on using a natural ACE (angiotensin converting enzyme) inhibitor typically used to treat high blood pressure to also treat lung injuries has entered phase II clinical trials to measure the drug’s effectiveness compared to a placebo. Oudit is also working to develop clinical trials for using the natural ACE inhibitor on patients with heart failure.

Oudit’s research could lead to several discoveries that will help heart failure patients live better and longer lives.